Join the discussion — anonymously
Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.
Comments (2)
Yeah, I've noticed it too. Seems like every department is getting the memo. It's hard not to draw conclusions when the focus shifts so dramatically. While I understand the need to be lean, the lack of clear communication about what this actually means for roles or the company's direction is unsettling. Hopefully, it's just a standard business cycle adjustment and not something more concerning.
It's definitely a topic of conversation. My take is that with the Humira patent cliff looming, the company is proactively looking for ways to bolster the bottom line and invest in the pipeline. It's smart business, but I agree, the way it's being communicated internally could be better. Transparency about the goals and expected outcomes would ease a lot of the anxiety.